Streptozocin
- Generic Name
- Streptozocin
- Brand Names
- Zanosar
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15N3O7
- CAS Number
- 66395-18-4
- Unique Ingredient Identifier
- 8H27GUR065
- Background
An antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals.
- Indication
For the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
- Associated Conditions
- Metastatic Islet Cell Carcinoma
- Associated Therapies
- -
Two Chemotherapy Regimens Plus or Minus Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 140
- Registration Number
- NCT03351296
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇫🇷CHU de Caen, Caen, Calvados, France
🇫🇷ICM Val d'Aurelle, Montpellier, Hérault, France
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 1
- Registration Number
- NCT00609765
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2013-08-07
- Target Recruit Count
- 84
- Registration Number
- NCT00602082
- Locations
- 🇬🇧
Basildon University Hospital, Basildon, England, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Mid Kent Oncology Centre at Maidstone Hospital, Maidstone, England, United Kingdom
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
- Conditions
- Interventions
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT00448136
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
- Conditions
- Interventions
- First Posted Date
- 2004-10-20
- Last Posted Date
- 2016-09-21
- Target Recruit Count
- 304
- Registration Number
- NCT00094497
- Locations
- 🇺🇸
National Cancer Institute - Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸University of Michigan, Department of Internal Medicine, Ann Arbor, Michigan, United States
🇦🇺Royal Adelaide Hospital, Adelaide, Australia
Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2004-08-16
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00003543
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 35
- Registration Number
- NCT00004688
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.